StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 2.0
Power Rank trend -> Falling
07/26/2024 16:09:00 EST
Moderna Inc (MRNA)
Industry: Biotechnology
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, MRNA has been trading in a range between $125.14 and $115.95 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
The AI powered stock chart is in a Red zone currently. We would avoid this stock.
Upside / Downside Potential
Moderna Inc $MRNA entered a Red zone 22 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $167.65, a potential upside of 37.29% from the recent price of 122.11. The stock is trading 39.6% (potential upside) below its 52 week high of $170.47 and 95.22 % (potential downside) above its 52 week low of $62.55 - based on the recent price.
Company Summary
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
News
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. (“Moderna” or the “Company”) (NASDAQ: MRNA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. Source: GlobeNewsWire Fri, 26 Jul 2024 10:37:00 -0400 Sentiment: Neutral |
| Moderna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy? Investors will likely focus on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings. Source: Zacks Investment Research Fri, 26 Jul 2024 09:41:04 -0400 Sentiment: Neutral |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA NEW YORK , July 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ: MRNA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. Source: PRNewsWire Wed, 24 Jul 2024 20:00:00 -0400 Sentiment: Neutral |
| Why Moderna (MRNA) Dipped More Than Broader Market Today The latest trading day saw Moderna (MRNA) settling at $121.25, representing a -1.02% change from its previous close. Source: Zacks Investment Research Tue, 23 Jul 2024 18:56:21 -0400 Sentiment: Neutral |
| Carlyle Group co-founder David Rubenstein joining Moderna's board Moderna Inc. said Tuesday that Bob Langer, one of its founders, will retire from the board and that Carlyle Group Inc. co-founder David Rubenstein will become a director on Aug. 5. Source: Market Watch Tue, 23 Jul 2024 10:19:00 -0400 Sentiment: Positive |
Technicals 52 Week Hi: 170.47 52 Week Low: 62.55 Beta: 1.662 50 Day MA: 134.1435 200 Day MA: 105.399 Earnings / Revenue Trends Qtr Earnings Growth YOY: -0.851 Qtr Revenue Growth YOY: -0.91 Forward PE: 32.4675 Trailing PE: 0